

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION OF THE GROUP'S PRODUCTS - MEROPENEM FOR INJECTION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Meropenem for Injection (Specification: 0.25g; 0.5g) submitted by Zhuhai United Laboratories Co. Ltd., a wholly-owned subsidiary of the Company, with the approval of National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs (the "Consistency Evaluation").

Being a carbapenem antibiotic with broad spectrum, meropenem for injection features reliable action to  $\beta$ -lactamase. It is clinically applicable to the treatment of infections caused by single or multiple meropenem-sensitive bacteria in adults and children, such as pneumonia (including nosocomial acquired pneumonia), urinary tract infection, intra-abdominal infection, gynecological infection, skin and soft tissue infection, meningitis, septicemia, etc. Currently, meropenem is listed in Category B in the National Medical Insurance Drug List (2022 version).

The approval will further help the Company to consolidate the advantageous position in the anti-infection field. The Company will continue to commit itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 6 September 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.